Fig. 8
MKC8866 reduces tumor regrowth post-paclitaxel withdrawal. Xenografts were established by subcutaneously injecting 5 × 106 MDA-MB-231 cells into the right flank of female athymic nude mice (Crl:NU(Ncr)-Foxn1nu, Charles River). When tumors were palpable (250 mm3) mice were randomized into groups and treatments initiated. Paclitaxel (7.5 mg kg−1 by intravenous injection) was administered every second day until day 10 (last dose indicated by the black arrow) as a single agent or in combination with MKC8866 (300 mg kg−1 by oral gavage). MKC8866 treatment was administered daily from day 1 to 28 (last dose indicated by the red arrow). Tumor size was assessed every 2–3 days via caliper measurement and tumor volume calculated (n = 10 mice per group). *P < 0.05, **P < 0.01 based on a Student’s t test. Error bars represent s.e.m.
